Protecting clinical trial participants and protecting data integrity: Are we meeting the challenges?

PLoS Medicine

Volumn 9, Issue 6, 2012, Pages 4-

  Ellenberg, Susan S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB;

ARTICLE; CLINICAL TRIAL PARTICIPANT; CONFLICT OF INTEREST; DATA ANALYSIS; EARLY TERMINATION OF CLINICAL TRIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL RESEARCH; MISCELLANEOUS NAMED GROUPS; PROFESSIONAL STANDARD; CLINICAL TRIAL (TOPIC); COMPUTER SECURITY; HUMAN EXPERIMENT; PATIENT PARTICIPATION; REVIEW; STANDARD;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; COMPUTER SECURITY; EARLY TERMINATION OF CLINICAL TRIALS; HUMAN EXPERIMENTATION; HUMANS; PATIENT PARTICIPATION;

EID: 84864651857     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001234     Document Type: Article

References (41)

1. Heart Special Project Committee (1988) Organization, review and administration of cooperative studies: a report from the Heart Special Projects Committee to the National Advisory Heart Council, May 1967. Control Clin Trials 9: 137-148.
2. Pocock SJ, (1977) Group sequential methods in the design and analysis of clinical trials. Biometrika 64: 191-199.
3. O'Brien PC, Fleming TR, (1979) A multiple testing procedure for clinical trials. Biometrics 35: 549-556.
4. Lan KKG, DeMets DL, (1983) Discrete sequential boundaries for clinical trials. Biometrika 70: 659-663.
5. Whitehead J, (1983) The design and analysis of sequential clinical trials New York Halsted Press.
6. Ellenberg SS, Geller N, Simon R, Yusuf S, eds. (1993) Proceedings of "Practical Issues in Data Monitoring of Clinical Trials." Stat Med 12: 415-616.
7. Ellenberg SS, Fleming TR, DeMets DL, (2002) Data monitoring committees in clinical trials: a practical perspective Chichester John Wiley & Sons, Ltd.
8. DeMets DL, Furberg CD, Friedman LM, (2006) Data monitoring in clinical trials a case studies approach New York Springer.
9. Herson J, (2009) Data and safety monitoring committees in clinical trials Boca Raton Chapman & Hall.
10. National Institutes of Health (1998) NIH policy for data and safety monitoring. Available: http://grants.nih.gov/grants/guide/notice-files/not98-084.html. Accessed 15 October 2011.
11. Food and Drug Administration (2006) Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees. Available: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf. Accessed 15 October 2011.
12. European Medicines Agency Committee for Medicinal Products for Human Use (2005) Guideline on data monitoring committees. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf. Accessed 15 October 2011.
13. World Health Organization (2005) Operational guidelines for the establishment and functioning of data and safety monitoring boards. Available: http://whqlibdoc.who.int/hq/2005/TDR_GEN_Guidelines_05.1_eng.pdf. Accessed 15 October 2011.
14. Grant AM, Sydes M, McLeer S, Clemens F, Altman DG, et al. (2005) Issues in data monitoring and interim analysis of trials (the DAMOCLES study). Health Technology Assess 9: 1-238.
15. Sydes MR, Spiegelhalter DJ, Altman DG, Babiker AB, Parmar MK, et al. (2004) Systematic qualitative review of the literature on data monitoring committees for randomized controlled trials. Clin Trials 1: 60-79.
16. Sydes MR, Altman DG, Babiker AB, Parmar AK, Spiegelhalter DJ, et al. (2004) Reported use of data monitoring committees in the main published reports of randomized controlled trials. Clin Trials 1: 48-59.
17. Presley H., Vioxx and the Merck team effort. The Kenan Institute for Ethics at Duke University. Available: http://www.duke.edu/web/kenanethics/CaseStudies/Vioxx.pdf. Accessed 15 October 2011.
18. Drazen JM, Wood AJJ, (2010) Don't mess with the DSMB. N Eng J Med 363: 477-478.
19. Menikoff J, (2010) The paradoxical problem with multiple-IRB review. N Eng J Med 363: 1591-1593.
20. Klitzman R, (2011) How local IRBs view central IRBs in the US. BMC Medical Ethics 12: 13 http://www.biomedcentral.com/1472-6939/12/13. Accessed 20 April 2012.
21. Wittes J, Barrett-Conner E, Braunwald E, Chesney M, Cohen HJ, et al. (2007) Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. Clin Trials 4: 218-234.
22. Mondero TH, (2009) Data safety monitoring boards: a word from a sponsor (NHLBI). Transfusion 49: 1537-1539.
23. Dixon DO, Weiss S, Cahill K, Fox L, Love J, et al. (2011) Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials. Clin Trials 8: 727-735.
24. National Heart, Lung, and Blood Institute (October 2011) NHLBI policy for data and safety monitoring of extramural clinical studies. Available: http://www.nhlbi.nih.gov/funding/policies/dsmpolicy.htm. Accessed 20 April 2012.
25. DeMets DL, Fleming TR, (2004) The independent statistician for data monitoring committees. Stat Med 23: 1513-1517.
26. Siegel JP, O'Neill RT, Temple R, Campbell G, Foulkes MA, (2004) Independence of the statistician who analyses unblinded data. Stat Med 23: 1527-1529.
27. Pocock SJ, (2004) A major trial needs three statisticians: why, how and who? Stat Med 23: 1535-1539.
28. Ellenberg SS, George SL, (2004) Should statisticians reporting to a data monitoring committee be independent of the trial sponsor and leadership? Stat Med 23: 1503-1505.
29. Wittes J, (2004) Playing safe and preserving integrity: making the FDA model work. Stat Med 23: 1523-1525.
30. McPherson K, (1974) Statistics: the problem of examining accumulating data more than once. N Engl J Med 290: 501-502.
31. Pocock SJ, (1992) When to stop a clinical trial. BMJ 305: 235-240.
32. Ellenberg S, Geller N, Simon R, Yusuf S, eds. Proceedings of "Practical Issues in Data Monitoring of Clinical Trials." Stat Med 12: 521-525.
33. Bassler D, Montori V, Briel M, Glasziou P, Guyatt G, (2008) Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epid 61: 241-246.
34. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, et al. (2010) Stopping randomized trials early for benefit and estimation of treatment effects. JAMA 303: 1180-1187.
35. Berry SM, Carlin BP, Connor J, (2010) Bias and trials stopped early for benefit (letter). JAMA 304: 156.
36. Goodman S, Berry D, Wittes J, (2010) Bias and trials stopped early for benefit (letter). JAMA 304: 157.
37. Korn EL, Friedlin B, Mooney M, (2010) Bias and trials stopped early for benefit (letter). JAMA 304: 157-158.
38. Ellenberg SS, DeMets DL, Fleming TR, (2010) Bias and trials stopped early for benefit (letter). JAMA 304: 158.
39. Wheatley K, Clayton D, (2003) Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML 12 randomization. Control Clin Trials 24: 66-70.
40. DeMets DL, Fleming TR, Rockhold F, Massie B, Merchant T, et al. (2004) Liability issues for data monitoring committee members. Clin Trials 1: 525-531.
41. Tereskerz PM, (2010) Data safety monitoring boards: legal and ethical considerations for research accountability. Account Res 17: 30-50.